OPKO Health, Inc. OPK, a multinational biopharmaceutical and
diagnostics company, today announced that the United States Patent and
Trademark Office granted OPKO a patent covering RAYALDEE™, the Company's
product to treat secondary hyperparathyroidism (SHPT) in patients with stage 3
or 4 chronic kidney disease (CKD) and vitamin D insufficiency. The new patent
(US Pat. No. 8,778,373) provides OPKO with additional intellectual property
protection covering controlled release administration of a vitamin D compound.
OPKO is on schedule to announce top-line results from the first pivotal phase
3 trial for RAYALDEE in the third quarter of 2014 and file a New Drug
Application (NDA) with the FDA in the first quarter of 2015.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in